You Are Here:
This topic is in the process of being updated. Please go to the Update in Progress section to see the latest documents available.
This topic page summarizes the U.S. Preventive Services Task Force (USPSTF) recommendations on preventive medications for breast cancer.
Release Date: July 2002
- The USPSTF recommends against the routine use of tamoxifen or raloxifene for the primary prevention of breast cancer in women at low or average risk for breast cancer. (Go to the Clinical Considerations for a discussion of risk.)
Grade: D Recommendation.
- The USPSTF recommends that clinicians discuss chemoprevention with women at high risk for breast cancer and at low risk for adverse effects of chemoprevention. Clinicians should inform patients of the potential benefits and harms of chemoprevention.
Grade: B Recommendation.
Update in Progress
In an effort to make the USPSTF recommendations clearer and its processes more transparent, the Task Force is sharingmany of its documents for public comment, including draft Research Plans and draft Recommendation Statements. As a result, the final Recommendation Statement is not yet available.
The research team at the Evidence-based Practice Center independently gathers and reviews the available published evidence to address the questions posed by the USPSTF. The resulting draft Evidence Report is critiqued by national subject matter experts before being finalized.
|Evidence Report||Related Items|
|Evidence Report (PDF File, 225 KB; PDF Help)||Comparative Effectiveness Review (PDF File, 4.5 MB; PDF Help)|
The USPSTF reviews the Evidence Report, evaluates the benefits and harms of the clinical preventive service, and discusses and develops one or more preliminary specific recommendations. The resulting draft Recommendation Statement is posted on this Web site for public comment before being finalized.
|Recommendation Statement||Related Items|
|Draft Recommendation Statement for Public Comment*
(April 16–May 13, 2013)
|Consumer Fact Sheet (PDF File, 70 KB; PDF Help)|
* Note: Draft Recommendation Statements are by their nature not final, and should not be interpreted as to represent official USPSTF recommendations for practice. Draft Recommendation Statements are provided by the USPSTF for informational purposes only.
Current as of May 2013
Chemoprevention of Breast Cancer, Topic Page. U.S. Preventive Services Task Force. http://www.uspreventiveservicestaskforce.org/uspstf/uspsbrpv.htm